Skip to main content

Table 2 Baseline characteristics of patients with serous retinopathy compared with the overall coBRIM population

From: Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

  Cobimetinib + vemurafenib recipients with SR (n = 63) Placebo + vemurafenib recipients with SR (n = 7) Overall coBRIM population (N = 493)
Age, years
 Median 59 62 55
 Range 30–78 33–76 23–88
Sex, n (%)
 Male 37 (58.7) 2 (28.6) 286 (57.8)
 Female 26 (41.3) 5 (71.4) 209 (42.2)
Region, n (%)
 Europe 51 (80.9) 5 (71.4) 366 (73.9)
 Australia/New Zealand 8 (12.7) 2 (28.6) 78 (15.8)
 North America 4 (6.4) 0 51 (10.3)
  1. SR serous retinopathy